News
Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023 700 900 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

ROCKVILLE, MARYLAND, October 31st, 2023 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain from October 20th to 24th. ICT…

Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting 1600 1868 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

ROCKVILLE, MARYLAND, May 24th, 2023 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual meeting in Los Angeles, California. May…

Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting

ROCKVILLE, MARYLAND, May 2nd, 2023 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida April 14-19, 2023. ICT presented GCC19CART,…

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer 1366 907 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer

ROCKVILLE, MARYLAND, August 18, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the first patient has been enrolled in its Phase I trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC).…

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ROCKVILLE, MARYLAND, May 26th, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the acceptance of an abstract for poster presentation at the upcoming 2022 ASCO Annual meeting in Chicago, IL from June 3-7,…

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

ROCKVILLE, MARYLAND, May 17th, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual meeting in Washington DC. May…

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting   1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting  

Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose of 2×10^6 CAR T cells / kg demonstrating a 57% (4/7) objective response rate.   Pre-Clinical Data demonstrates CoupledCAR® technology promotes efficient in vivo expansion and superior functionality…

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer

GCC19CART is an autologous CAR T therapy candidate that has shown promising results in over 30 R/R mCRC patients in China  ICT plans to initiate a Phase 1 Trial of GCC19CART in the U.S. for the Treatment of R/R mCRC in mid-2022  ROCKVILLE, MARYLAND, April 19, 2022 (GLOBE NEWSWIRE) – Innovative Cellular Therapeutics, Inc. (ICT),…

Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Robert Dallimore as SVP of Quality & Compliance.   “I am very pleased to welcome Rob to ICT. This is a critical time for the…

Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Lucy Lu, M.D. as Chief Operations Officer.   “We are excited to welcome Lucy to the team during this critical time for the company,” said…